|
|
|
International Clinical Trials
|
In the history of medical research, the concept of patient centricity is a relatively new one. Until a few years ago, the primary focus of most clinical trials was developing drugs for commercial application. Patients were important and necessary to this process, but only because they represented the human connection to data the development team needed to move a drug candidate or treatment option through the regulatory approval process.
Unsurprisingly, patients who did become involved in clinical trials often felt disrespected and unimportant. As the industry accepted that patients’ generally low levels of satisfaction translated into compliance issues and high dropout rates, as well as broadly negative perceptions of clinical research that contribute to the limited participation rates of today, interest began to rise in assessing and addressing patient concerns.
By the mid-2000s, terms such as ‘patient centricity’ and ‘patientcentric trials’ had begun to find their way into publications and presentations. Although precise definitions vary, the underlying concept from the beginning is that providing patients with more information and greater integration into the trial process will lead to greater patient satisfaction and improved outcomes for sponsors, research centres, and patients. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Porton Biopharma opens new facility to make more of its childhood cancer cure
In a ribbon cutting ceremony, John Glen MP for Salisbury and South
Wiltshire today (27th April 2018) officially opened Porton Biopharma
Limited’s (PBL) new fermentation facility which will be used to
manufacture the company’s life-saving leukaemia drug Erwinase®.
More info >> |
|
 |
White Papers |
 |
|
Competitive Drive: The Challenges of a Globalised Packaging Industry
Aesica Pharmaceuticals
Packaging is becoming an increasingly competitive and lucrative industry globally. Jeremy Drummond PhD of Aesica Formulated Products looks at the challenges and opportunities this presents.
More info >> |
|
 |
Industry Events |
 |
SMI Immuno-Oncology Conference
25-27 September 2018, Copthorne Tara Hotel, London, UK
Immuno-Oncology is a fast-paced field with massive potential to deliver
successful and durable cancer therapies, and SMi's Immuno-Oncology Conference will focus on a few key areas of
the field with a representation of the whole industry under each area. These
areas will be drawn together to look towards the future of Immuno-oncology and
how the field can progress.
More info >> |
|
|
